Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3450-3456

  Richards, Christopher J ^a   Je, Youjin ^b   Schutz, Fabio A B ^a,d   Heng, Daniel Y C ^e   Dallabrida, Susan M ^c   Moslehi, Javid J ^a   Choueiri, Toni K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BIOGEN   (United States)

^d HOSPITAL SÃO JOSÉ   (Brazil)

^e UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ARTICLE; CANCER INCIDENCE; CANCER MODEL; CANCER PATIENT; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; DRUG SAFETY; GENETIC HETEROGENEITY; HUMAN; INCIDENCE; KIDNEY CARCINOMA; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PUBLISHING; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; INCIDENCE; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052709825     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.4309     Document Type: Article

References (52)

1. Ghoreschi K, Laurence A, O'Shea JJ: Selectivity and therapeutic inhibition of kinases: To be or not to be? Nat Immunol 10:356-360, 2009
2. Demetri GD, Van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
3. Motzer RJ, Hutson TE, Tomczak P, et al: Suntinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
4. ClinicalTrials.gov: List results, search of sunitinib. http://www.clinicaltrials.gov/ct2/results?term=sunitinib
5. Pfizer: Sutent prescribing information. http://www.pfizer.com/files/ products/uspi-sutent.pdf
6. Choueiri TK, Schutz FA, Je Y, et al: Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol 28:2280-2285, 2010
7. Chu D, Lacouture ME, Weiner E, et al: Risk of hand-foot skin reaction with multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: A meta-analysis. Clin Genitourin Cancer 7:11-9, 2009
8. Je Y, Schutz FA, Choueiri TK: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974, 2009
9. Schmidinger M, Zielinski CC, Vogl UM, et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212, 2008
10. Zhu X, Stergiopoulos K, Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncology 48:9-17, 2009
11. Choueiri TK, Mayer EL, Je Y, et al: Congestive heart failure risk in breast cancer patients treated with bevacizumab. J Clin Oncol 29:632-638, 2011
12. Chu D, Lacouture ME, Fillos T, et al: Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 47:176-186, 2008
13. Nalluri SR, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 19:2277-2285, 2008
14. Ranpura V, Hapani S, Chuang J, et al: Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis in bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol 49:287-297, 2010
15. Ranpura V, Pulipati V, Chu D, et al: Increased risk of high-grade hypertension with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens 23:460-468, 2010
16. Wu S, Chen JJ, Kudelka A, et al: Incidence and risk of hypertension with sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9:117-123, 2008
17. Wu S, Kim C, Baer L, et al: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381-1389, 2010
18. Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344, 2007 (Pubitemid 46652481)
19. Giordano FJ, Gerber HP, Williams SP, et al: A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci 98:5780-5785, 2001 (Pubitemid 32435719)
20. Deuse T, Peter C, Fedak PW, et al: Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 120:S247-S254, 2009
21. Reference deleted
22. Moher D, Liberati A, Tetzlaff J, et al: Preferred reporting items for systematic reviews and meta-anlayses: The PRISMA statement. J Clin Epidemiol 62:1006-1012, 2009
23. Hopewell S, Clarke M, Moher D, et al: CONSORT for reporting randomised trials in journal and conference abstracts. Lancet 371:281-283, 2008
24. National Cancer Institute: Common Toxicity Criteria version 3. http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ctcaev3. pdf
25. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
26. Escudier B, Roigas J, Gillessen S, et al: Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27:4068-4075, 2009
27. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
28. Lundh A, Gøtzsche PC: Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 8:22, 2008
29. Jadad AR, Moore A, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17:1-12, 1996 (Pubitemid 26120810)
30. Wells GA, Shea B, O'Connell D, et al: The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
31. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003 (Pubitemid 37088507)
32. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 7:177-188, 1986 (Pubitemid 17189972)
33. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088-1101, 1994
34. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634, 1997 (Pubitemid 27387172)
35. Gore ME, Szczylik C, Porta C, et al: Safety and efficacy for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 10:757-763, 2009
36. Kontovinis LF, Papazisis KT, Touplikioti P, et al: Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: Clinical outcomes and plasma angiogenesis markers. BMC Cancer 9:82-92, 2009
37. Motzer RJ, Michaelson MD, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16-24, 2006 (Pubitemid 46630489)
38. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006 (Pubitemid 43854967)
39. Tomita Y, Shinohara N, Yuasa T, et al: Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol 40:1166-1172, 2010
40. Matsumoto K, Sawaki A, Mizuno N, et al: Clinical efficacy and safety of sunitinib after imatinib failure in Japanese patients with gastrointestinal stromal tumor. Jpn J Clin Oncol 41:57-62, 2011
41. Mackay HJ, Tinker A, Winquist E, et al: A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCI CTG Trial IND.184. Gynocol Oncol 116:163-167, 2010
42. Dror Michaelson M, Regan MM, Oh WK, et al: Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913-920, 2009
43. Kulke MH, Lenz HJ, Meropol NJ, et al: Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410, 2008
44. Saltz LB, Rosen LS, Marshall JL, et al: Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799, 2007 (Pubitemid 350086483)
45. Hensley ML, Sill MW, Scribner DR Jr, et al: Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: A gynecologic oncology group phase II study. Gynocol Oncol 115:460-465, 2009
46. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: The SOLVD Investigators. N Engl J Med 327:685-691, 1992
47. Ewer MS, Suter TM, Lenihan DJ, et al: Cardiovascular adverse events (CV-AES) in a pooled analysis of 1090 patients (PT) from phase 3 suntinib (SU) trials. Ann Oncol 21:viii166, 2010 (suppl 8; abstr 506P)
48. Hutson TE, Procopio G, Escudier S, et al: Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos). J Clin Oncol 28:15s, 2010 (suppl; abstr 4614)
49. Chintalgattu V, Ai D, Langley RR, et al: Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J Clin Invest 120:472-484, 2010
50. Kerkela R, Woulfe KC, Durand JB, et al: Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci 2:15-25, 2009
51. Bennett CL, Silver SM, Djulbegovic B, et al: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914-924, 2008 (Pubitemid 351397066)
52. Chou R, Helfand M: Challenges in systematic reviews that assess treatment harms. Ann Intern Med 142:1090-1099, 2005 (Pubitemid 40847712)